Bazedoxifene

Drug Profile

Bazedoxifene

Alternative Names: Bazedoxifene acetate; Bazedoxifeno; Brilence; Conbriza; TSE-424; Viviant; WAY 140424; WAY-TSE 424

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ligand Pharmaceuticals; Wyeth
  • Developer Almirall S.A.; Ligand Pharmaceuticals; Pfizer
  • Class Azepines; Calcium regulators; Indoles; Osteoporosis therapies; Phenols; Small molecules
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Postmenopausal osteoporosis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 07 Apr 2015 Bazedoxifene is still in Preregistration for Postmenopausal osteoporosis (Treatment and Prevention) in USA
  • 07 Apr 2015 Launched for Postmenopausal osteoporosis in Germany, Lithuania, Sweden, Croatia and Israel (PO) before April 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top